drugset
drugset / Trial / NCT06823063

Clinical Trial of Human Umbilical Cord Mesenchymal Stem Cells (IxCell hUC-MSC-P) in the Treatment of CTD-ILD

NCT06823063 ↗

Phase 1 Not yet recruiting 18 enrolled Shanghai IxCell Biotechnology Co., LTD
Non-randomizedParallel-groupOpen-labelTreatment

Summary

To evaluate the safety and tolerability of IxCell hUC-MSC-P in the treatment of patients with connective tissue disease-related interstitial lung disease. To evaluate the efficacy, pharmacokinetics and immunogenicity of IxCell hUC-MSC-P in the treatment of connective tissue disease-associated interstitial lung disease (CTD-ILD).

Timeline

Start
2025-04-01
Primary completion
2026-10-30
Completion
2026-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject IxCell hUC-MSC-P Cell therapy 5e+07 cells Intravenous
Subject IxCell hUC-MSC-P Cell therapy 1e+08 cells Intravenous
Subject IxCell hUC-MSC-P Cell therapy 2e+08 cells Intravenous

Indications

interstitial lung disease